** Shares of medical technology co Artrya AYA.AX rise 9.4% to A$0.875
** Stock hits its highest level since January 20
** Co secures U.S. Food and Drug Administration (FDA) clearance for commercial sale of Salix Coronary Anatomy in the United States
** Salix is the first point of care approach for assessing coronary artery disease, says co
** About 1.9 million shares change hands, 9.7 times the 30-day average volume of shares
** Stock up 50.9% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。